Tumor Necrosis Factor Inhibitors Market and Ongoing Clinical Pipeline Outlook 2022

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

Introduction to Tumor Necrosis Factor (TNF)
1.1 Basic Structure of the Tumor Necrosis Factor (TNF) Molecule
1.2 Significance of Tumor Necrosis Factor for the Biosynthesis Regulation
1.2.1 Regulation of TNF Biosynthesis at the Transcriptional Level
1.2.2 Regulation the TNF at the Receptor Level
1.3 Tumor Necrosis Factor Receptors

Tumor Necrosis Factor Receptor Signaling Pathway
2.1 Tumor Necrosis Factor Receptor1 (TNFR1) Signaling
2.2 Tumor Necrosis Factor Receptor 2 (TNFR 2) Signaling

Overview of Tumor Necrosis Factor Inhibitors
3.1 Mechanism of Action of Tumor Necrosis Factor Inhibitors
3.2 Mechanism of Action of Remicade in the Inflammatory Diseases
3.3 Mechanism of Action of the Etanercept
3.4 Mechanism of Action of Humira

Approaches Used in Development of Anti-TNF
4.1 Monoclonal Antibody Approach
4.2 Recombinant DNA Technology Approach

Function of TNF in Immune Mediated Inflammatory Diseases
5.1 Rheumatoid Arthritis
5.2 Crohn's Disease
5.3 Psoriasis and Psoriatic Arthritis

Involvement of TNF and its Receptor in Neurodegenerative Disorders
6.1 Alzheimer’s Diseases
6.2 Parkinson’s Diseases
6.3 Ischemic Stroke
6.4 Multiple Sclerosis

Role of the Tumor Necrosis Factor in the Development of the Cancer
7.1 Introduction
7.2 Tumor Necrosis Factor as Carcinogen
7.3 Tumor Necrosis Factor as an Anti-Cancer Agent

TNF Inhibitors Market Overview
8.1 Market of Anti-TNF Blockbuster Drugs
8.1.1 Market of Humira
8.1.2 Market of Enbrel
8.1.3 Market of Remicade
8.2 Global Tumor Necrosis Factor Inhibitors Pipeline Overview

Global TNF Inhibitors Market Dynamics
9.1 Accelerative Parameters to the TNF Inhibitor Market
9.2 Challenges to the TNF Inhibitor Market

Future Implications of TNF Inhibitor Market

Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication and Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered

Marketed Tumor Necrosis Factor Inhibitors Clinical Insight
12.1 Lumbricus Rubellus Extract (Disolf)
12.2 Certolizumab Pegol (Cimzia, Simziya)
12.3 Apremilast (Otezla)
12.4 Lenalidomide (Ladevina, Revlimid)
12.5 Adalimumab (Humira, Raheara)
12.6 Etanercept (Enbrel)
12.7 Infliximab Biosimilar (Inflectra, Remsima)
12.8 Adalimumab Biosimilar
12.9 Pomalidomide (Imnovid, Pomalyst)
12.10 Belimumab (Benlysta)
12.11 Etanercept Biosimilar (Infinitam)
12.12 Golimumab (Simponi)
12.13 Infliximab Biosimilar (Infimab)
12.14 Infliximab (Remicade)
12.15 Etanercept Biosimilar (Intacept)
12.16 Iguratimod (Careram, Kolbet)
12.17 Thalidomide (Thaled, Thalidomide Celgene, Thalomid)
12.18 Infliximab Biosimilar
12.19 Adalimumab Biosimilar (Exemptia)
12.20 Etanercept Biosimilar (Iran)
12.21 Etanercept Biosimilar (Etacept, Etanar, Yisaipu)
12.22 Iguratimod
12.23 Anti-Tumour Necrosis Factor-Alpha Antibody Oral
12.24 Pentoxifylline (Claudicat, Dospan Pento, Elorgan, Pentoxifilina, Trental)
12.25 Sho-seiryu-to

TNF Inhibitors Suspended in Clinical Pipeline
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

Competitive Landscape
14.1 AbbVie
14.2 Ablynx
14.3 Apogenix
14.4 AryoGen Biopharma
14.5 Bionovis
14.6 CASI Pharmaceuticals
14.7 Celltrion
14.8 Celgene Corporation
14.9 Delenex Therapeutics
14.10 Dexa Medica
14.11 EPIRUS Biopharmaceuticals
14.12 Janssen Biotech
14.13 GlaxoSmithKline
14.14 HanAll Biopharma
14.15 Intas Pharmaceuticals
14.16 LEO Pharma
14.17 LG Life Sciences
14.18 MedImmune
14.19 Momenta Pharmaceuticals
14.20 Novartis
14.21 PROBIOMED
14.22 Reliance Life Sciences
14.23 Sandoz
14.24 Samsung Bioepis
14.25 Sanofi-Aventis
14.26 Shanghai CP Guojian Pharmaceutical
14.27 Shanghai Pharmaceuticals
14.28 Simcere Pharmaceutical
14.29 Toyama Chemical
14.30 Tsumura
14.31 UCB
14.32 Zydus Cadila

Figure 1-1: Structure of the Tumor Necrosis Factor Molecule
Figure 1-2: Regulation of the Tumor Necrosis Factor Biosynthesis and Bioavailability
Figure 1-3: Structure of Tumor Necrosis Factor Receptor 1
Figure 1-4: Structure of Tumor Necrosis Factor Receptor 2
Figure 2-1: Signaling Pathway of Tumor Necrosis Factor Receptor1 (TNFR1)
Figure 2-2: Tumor Necrosis Factor Receptor 2 Signaling Pathway (TNFR 2)
Figure 3-1: Remicade Mechanism of Action
Figure 3-2: Etanercept Mode of Action
Figure 3-3: Humira Mechanism of Action
Figure 4-1: Methods for the Anti-TNF Production
Figure 5-1: Tumor Necrosis Factor in Rheumatoid Arthritis
Figure 5-2: Global - Top Anti-Rheumatic Drug Sales (US$ Million), 2015 and 2022
Figure 5-3: Anti-TNF Therapy for the Treatment of Rheumatoid Arthritis
Figure 5-4: Molecular Targets of TNF Antagonists in Crohn’s Disease
Figure 5-5: Tumor Necrosis Factor in Psoriatic Arthritis
Figure 7-1: Tumor Necrosis Factor in the Cancer Initiation
Figure 7-2: Role of Tumor Necrosis Factor as an Anti-Cancer Agent
Figure 8-1: Blockbuster Anti-TNF Drugs (US$ Billion), 2015
Figure 8-2: Blockbuster TNF Inhibitors for Rheumatic Disease (US$ Billion), 2015 and 2022
Figure 8-3: Humira - Global Sales (US$ Billion), 2011-2015 and 2022
Figure 8-4: Enbrel - Global Sales (US$ Billion), 2011-2015 and 2022
Figure 8-5: Market Price of Enbrel and Etacept (USD)
Figure 8-6: Remicade - Global Sales (US$ Billion), 2011-2015 and 2022
Figure 8-7: Market Price of Remicade and Infimab (USD)
Figure 8-8: Global - Tumor Necrosis Factor Inhibitors Pipeline by Phase (%), 2016 till 2022
Figure 8-9: Global - Tumor Necrosis Factor Inhibitors Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-10: Global - Tumor Necrosis Factor Inhibitors Suspended and Discontinued in Pipeline by Phase (%), 2016
Figure 8-11: Global - Tumor Necrosis Factor Inhibitors Suspended and Discontinued in Pipeline by Phase (Number), 2016
Figure 9-1: Favorable Parameters of Anti-TNF Drugs
Figure 9-2: Limitation Factors for the Anti-TNF Drug Market
Figure 14-1: Ablynx - Clinical Pipeline
Figure 14-2: Apogenix - Clinical Pipeline
Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
Figure 14-4: Celgene - Clinical Pipeline
Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
Figure 14-6: HanAll Biopharma - Clinical Pipeline
Figure 14-7: Novartis - Clinical Pipeline
Figure 14-8: Sandoz - Clinical Pipeline
Figure 14-9: Toyama Chemical - Clinical Pipeline
Figure 14-10: Zydus Cadila - Clinical Pipeline

Download Report: https://www.kuickresearch.com/report-tumor-necrosis-factor-inhibitors-market-and-clinical-pipeline-outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.